Refine
Has Fulltext
- yes (8)
Is part of the Bibliography
- yes (8)
Document Type
- Journal article (8)
Language
- English (8) (remove)
Keywords
- BRAF (2)
- PD-1 (2)
- immunohistochemistry (2)
- melanoma (2)
- B7-H1 Antigen (1)
- COX2 expression (1)
- CTLA-4 Antigen (1)
- Drug Therapy, Combination (1)
- Immune-related adverse event (1)
- Ipilimumab (1)
- Merkel cell carcinoma (1)
- Minimal change disease (1)
- NRF2 (1)
- Nivolumab (1)
- PRAME (1)
- Programmed Cell Death 1 Receptor (1)
- Skin Neoplasms (1)
- adjuvant treatment (1)
- avelumab (1)
- cell rich blue nevus (1)
- checkpoint blocker (1)
- common blue nevus (1)
- ipilimumab (1)
- lactate dehydrogenase (1)
- melanocytic markers (1)
- melanoma malignancy (1)
- nivolumab (1)
- resistance (1)
- rhabdoid differentiation (1)
- rhabdoid melanoma (1)
- satellitosis (1)
- skin (1)
- targeted therapy (1)
Institute
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (8)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (1)
- Medizinische Klinik und Poliklinik II (1)
- Physiologisches Institut (1)
- Rudolf-Virchow-Zentrum (1)
- Theodor-Boveri-Institut für Biowissenschaften (1)
Merkel cell carcinoma is a rare, highly aggressive skin cancer with neuroendocrine differentiation. Immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease with response rates to programmed cell death protein 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) inhibition of up to 62%. However, primary and secondary resistance to PD-1/PD-L1 inhibition remains a so far unsolved clinical challenge since effective and safe treatment options for these patients are lacking.Fourteen patients with advanced (non-resectable stage III or stage IV, Union international contre le cancer 2017) Merkel cell carcinoma with primary resistance to the PD-L1 inhibitor avelumab receiving subsequent therapy (second or later line) with ipilimumab plus nivolumab (IPI/NIVO) were identified in the prospective multicenter skin cancer registry ADOREG. Five of these 14 patients were reported previously and were included in this analysis with additional follow-up. Overall response rate, progression-free survival (PFS), overall survival (OS) and adverse events were analyzed.All 14 patients received avelumab as first-line treatment. Thereof, 12 patients had shown primary resistance with progressive disease in the first tumor assessment, while two patients had initially experienced a short-lived stabilization (stable disease). Six patients had at least one systemic treatment in between avelumab and IPI/NIVO. In total, 7 patients responded to IPI/NIVO (overall response rate 50%), and response was ongoing in 4 responders at last follow-up. After a median follow-up of 18.85 months, median PFS was 5.07 months (95% CI 2.43—not available (NA)), and median OS was not reached. PFS rates at 12 months and 24 months were 42.9% and 26.8 %, respectively. The OS rate at 36 months was 64.3%. Only 3 (21%) patients did not receive all 4 cycles of IPI/NIVO due to immune-related adverse events.In this multicenter evaluation, we observed high response rates, a durable benefit and promising OS rates after treatment with later-line combined IPI/NIVO. In conclusion, our patient cohort supports our prior findings with an encouraging activity of second-line or later-line IPI/NIVO in patients with anti-PD-L1-refractory Merkel cell carcinoma.